AI assistant
SHIELD THERAPEUTICS PLC Share Issue/Capital Change 2021
7914_sha_2021-09-30_229ef290-60dc-4bc4-b893-dc620e477196.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6311N
Shield Therapeutics PLC
30 September 2021
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 30 September 2021
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics Retention Share Plan | |||
| Period of return: | From: | 01 April 2021 | To: | 30 September 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 39,794 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 39,794 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
| Period of return: | From: | 01 April 2021 | To: | 30 September 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 388,079 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | -47,059 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 341,020 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
| Period of return: | From: | 01 April 2021 | To: | 30 September 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 24,273 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 24,273 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
| Period of return: | From: | 01 April 2021 | To: | 30 September 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 3,178,276 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,178,276 | |||
| Name of contact: | Lucy Huntington-Bailey |
| Telephone number of contact: | +44 (0) 191 511 8500 |
For further information, please contact:
| Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
| Greg Madison (CEO) Hans-Peter Rudolf (CFO) |
|||
| Peel Hunt LLP - Nominated Adviser & Joint Broker | +44 (0) 20 7148 8900 | ||
| James Steel / Christopher Golden | |||
| finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
| Geoff Nash / Alice Lane/ George Dollemore | |||
| Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
| Paul McManus / Lianne Cawthorne/ Alice Woodings | or [email protected] | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLREAKNEDAEFEFA